Meet our CannMed 2018 Advisory Board

Meet our CannMed 2018 Advisory Board

We take great pride in the quality of presentations delivered at CannMed events. It’s because CannMed attracts the greatest minds in cannabis research that many consider it to be the premier cannabinoid medicine conference.  

For CannMed 2018, we wanted the very scientists, researchers, physicians, and cultivators who are driving cannabis research and innovation to help guide our presenter selection process. That is why we established the CannMed 2018 Advisory Board. You can read more about each advisory board member below.

The CannMed 2018 Advisory Board provides leadership and guidance to the conference team to help them carry out the mission of CannMed Events, which is to gather the greatest minds in cannabis research for the purpose of furthering medical cannabis research, treatment, and product development. More specifically, The CannMed 2018 Advisory Board will be closely involved in selecting abstracts for the CannMed 2018 oral and poster presentations. 

If you would like to be considered for a CannMed presentation, you can submit your abstracts here.


Raphael Mechoulam, Ph.D.

Raphael Mechoulam is an Israeli organic chemist and professor of Medicinal Chemistry at the Hebrew University of Jerusalem in Israel. He is best known for his work (together with Y. Gaoni) in the isolation, structure elucidation and total synthesis of Δ9-tetrahydrocannabinol, the main active principle of cannabis and for the isolation and the identification of the endogenous cannabinoids anandamide from the brain and 2-arachidonoyl glycerol (2-AG) from peripheral organs together with his students, postdocs and collaborators.

Michael Dor, M.D.

Michael Dor is the MPA Chief Medical Consultant, Medical Cannabis Unit for the Ministry of Health in Jerusalem, Israel.  Dr Dor earned his medical degree at Tel Aviv University followed by his Diploma in Health Services and in Family Medicine through the Israeli Medical Association. Dr. Dor then completed his Masters in Public Administration at Harvard University – Kennedy School of Government. Dr. Dor’s commitment to providing quality healthcare for the people of Israel has led him to holding multiple leadership roles within his career, including Director of Emergency Walk-In Clinic – Jerusalem, Israel; Head of Community Medicine Division – Israeli Ministry of Health; and Deputy Director of All Medical Services – Israeli Ministry of Health. In 2014, he was honored with Presidential Award for volunteer work he did to establish a clinic for un-insurred illegal immigrant and victims of human trafficking. Today, Dr. Dor is active as a family physician and also serves as the Chief Medical Officer – Ministry of Foreign Affairs and the Medical Head Advisor of the Medical Cannabis Unit for the Israeli Ministry of Health.

Bonni Goldstein, M.D.

Bonni Goldstein, MD is the Medical Director of Canna-Centers, a California-based medical practice devoted to educating patients about the use of cannabis for serious and chronic medical conditions.  After years of working in the specialty of Pediatric Emergency medicine, she developed an interest in the science of medical cannabis after witnessing its beneficial effects in an ill friend.  Since then she has evaluated thousands of patients for use of medical cannabis.  She has a special interest in treating children with intractable epilepsy, autism, and advanced cancers, as well as adults with chronic pain, autoimmune illnesses and other endocannabinoid deficiency disorders. Dr. Goldstein recently authored the book “Cannabis Revealed: How the world’s most misunderstood plant is treating everything from chronic pain to epilepsy.”

A native of New Jersey, Dr. Goldstein received her undergraduate education at Rutgers College and her medical degree at Robert Wood Johnson Medical School at the University of Medicine and Dentistry of New Jersey.  Her post-doctoral education included internship and residency at Children’s Hospital Los Angeles.  Dr. Goldstein also served as Chief Resident at Children’s Hospital Los Angeles.  She was a Clinical Instructor in Pediatrics at USC School of Medicine in Los Angeles, Emergency Transport Attending Physician at Children’s Hospital Los Angeles and Emergency Medicine Attending Physician in the Pediatric Emergency Department at Los Angeles County-USC Medical Center.   She is a member of the Society of Cannabis Clinicians, the International Association of Cannabis as Medicine, and the International Cannabinoid Research Society.  Dr. Goldstein also serves on the Scientific Advisory Board for Courtagen Life Sciences, United Patients Group and United in Compassion Australia.  She is the medical advisor to

Dustin Sulak, D.O.

Dr. Dustin Sulak is an osteopathic general practitioner whose clinical practice focuses on treating refractory conditions in adults and children with an individualized, health-centered approach.  Dr. Sulak received undergraduate degrees in nutrition science and biology from Indiana University, a doctorate of osteopathy from the Arizona College of Osteopathic Medicine, and completed an osteopathic rotating internship at Maine-Dartmouth Family Medicine Residency.  Dr. Sulak is a founder of Integr8 Health, a medical practice in Maine that follows over 8,000 patients using medical cannabis,, a medical cannabis patient education resource, and Cannabis Expertise, a medical cannabis continuing medical education curriculum.  He sits on the board of directors and chairs the research committee of the Society of Cannabis Clinicians, and has lectured to healthcare providers internationally on the clinical applications of cannabis.

Catherine Jacobson

Dr. Catherine Jacobson is the Director of Clinical Research at Tilray, a federally licensed Canadian medical cannabis provider. She leads a global clinical research program of regulatory agency-approved trials aimed at generating methodologically sound data to inform treatment with medical cannabis products. Dr. Jacobson obtained a Ph.D. in Neuroscience from the Oregon Health & Science University, and completed post-doctoral fellowships at UCSF and Stanford. In 2013, Dr. Jacobson published the first account of treatment of pediatric epilepsy patients with medical cannabis preparations in the peer-reviewed journal Epilepsy & Behavior. This work led her back to UCSF for a clinical research fellowship at the Pediatric Epilepsy Center to investigate the anti-seizure potential of CBD in children with severe, treatment-resistant epilepsy. Her work now focuses on tackling some of the largest practical and scientific challenges facing medical cannabis use and research, with the goal of generating a strong evidence base to inform the use of medical cannabis preparations for specific diseases and symptoms. Dr. Jacobson also serves on the Medical Cannabis Advisory board to the State of California, where she advocates for medical cannabis products to meet product quality standards that ensure the safety and well-being of patients.

Kevin McKernan

Kevin is currently the CSO of Medicinal Genomics. Medicinal Genomics made worldwide news in 2011 when it publically released the first genome sequence for Cannabis Sativa L. As a result of this work, Medicinal Genomics (MGC) launched a suite of DNA-based cannabis testing tools to ensure patients have access to safe, quality cannabis, while also helping growers and producers identify desirable plant traits, detect harmful microbes, and increase yields.

Previously, Kevin held the position of Vice President and Director of R&D of Life Technologies where he managed the development of Life Technologies next generation SOLiD sequencing technology. Integral to the SOLiD R&D process, Kevin oversaw over 100 research collaborations exploring the new biological frontiers with next-generation sequencing and saw particular excitement and traction in human tumor sequencing. Kevin initiated an R&D project to investigate chemFET semiconductor-based DNA sequencing and spearheaded a process to acquire the DNA sequencing company, Ion Torrent, for $350M. These collaborations resulted in hundreds of publications and seven journal covers from Science Translational Medicine to Nature.

Kevin was the President and CSO of Agencourt Personal Genomics, a startup company he co-founded in 2005 to invent revolutionary sequencing technologies that dropped the cost of sequencing a human genome from $300M to $3,000; a 100,000-fold improvement in sequencing speed and cost in a few years. Kevin oversaw the growth and research for APG which was acquired by ABI in 2006. In 2000, Kevin co-founded Agencourt Biosciences Corporation and acted as the CSO until 2005 when it was acquired by Beckman Coulter who had an expressed interest in nucleic acid testing and blood diagnostics. From 1996 to 2000, Kevin managed the Research and Development Team for the Human Genome Project at Whitehead Institute/MIT which resulted in several patents for nucleic acid purification. Kevin holds a B.S. in Biology from Emory University with a focus on cloning and expressing Norepinephrine Transporters.

No Comments

Post A Comment